8215 results for "canc*"

in 11.18 milliseconds.

• Genome and transcriptome sequence data from a recurrent renal cell carcinoma patient

  Genome and transcriptome sequence data from a recurrent renal cell carcinoma patient,generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001016727

• Genome and transcriptome sequence data from a metastatic carcinoma of unknown primary (breast) patient

  Genome and transcriptome sequence data from a metastatic carcinoma of unknown primary (breast) patient,generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001016728

• Genome and transcriptome sequence data from a peripheral t cell lymphoma/transformation of mycosis fungoides patient

  Genome and transcriptome sequence data from a peripheral t cell lymphoma/transformation of mycosis fungoides patient,generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001016729

• Single-cell RNA-sequencing of cerebrospinal fluid identifies circulating tumour cells in children with brain cancer

  scRNA-seq paired fastq for 16 paediatric brain cancer patients and 33 samples

  Dataset EGAD00001016796

• IBCT-1 (Improved Breast Cancer Therapy) - WES

  This dataset comprises DNA whole-exome sequencing from a prospective, randomized neoadjuvant trial designed to evaluate DNA-based biomarkers for predicting carboplatin response in patients with early, high-risk breast cancer. The study enrolled 196 patients with with high-risk features, including triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) breast cancer subtypes. The final analysis included 187 patients, for which WES data is being made available for controlled access. Sample Composition Total samples: 373 (186 blood/normal + 187 tumor) - Blood samples: 186 (germline/reference) - Tumor samples: 187 (tumor tissue biopsies) Technical Specifications - Sequencing platform: Illumina HiSeq4000 - Read type: Paired-end - Read length: 2 × 76 bp - Library preparation: Twist Bioscience Human Comprehensive Exome Plus RefSeq v1 hybrid selection - DNA input: 100 ng per sample - Mean sequencing coverage: 46× for normal samples; 106× for tumor samples

  Dataset EGAD50000003091

• Identification of differentially expressed protein-coding genes in HCC and adjacent non-cancerous tissues

  Twenty samples were collected in pairs, i.e., HCC tissue and adjacent non-cancerous tissue. The collected tissue samples were stored in liquid nitrogen. First, 50 mg of tissue was lysed in TRIzol (Invitrogen) to extract RNA following the manufacturer’s instructions. Next, ribosomal RNA was depleted using a RiboZero Gold kit (Epicentre Bio-technologies). RNA integrity was assessed with an Agilent Bioanalyzer 2100. An RNA-Seq library was generated with the rRNA-depleted samples using an Illumina standard RNA Sample Prep kit according to the manufacturer’s instructions. The library was subsequently sequenced on an Illumina HiSeq2500 as 125-bp paired-ends with approximately 300-bp size selection.

  Dataset EGAD00001003397

• CNV detection in targeted NGS panel data

  We present targeted NGS panel data from 170 samples that were processed using the TruSightTM Cancer (TSC) panel (Illumina, San Diego, CA, USA), which targets 94 genes and 284 SNPs associated with a predisposition towards cancer. The samples are enriched for CNVs in the genes of interest. All CNVs have previously been assessed with MLPA and can therefore be considered as confirmed.

  Dataset EGAD00001003400

• Amplicon-based sequencing of drug resistant lung cancer cell lines (2017-07-05)

  A EGFR mutant NSCLC cell line which is sensitive to AZD9291 inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a AZD9291. Single cell derived colonies were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors hypothesised from currently available literature. This dataset contains all the data available for this study on 2017-07-05.

  Dataset EGAD00001003425

• June 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency as part of the International Human Epigenome Consortium.

  June 2017 data update (bam/fastq) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium.

  Dataset EGAD00001003414

• Exome and Transcriptome for pan-cancer gene-drug analysis

  Total of 584 tumor specimens and/or patient-derived cells across 14 cancer types were subjected for whole-exome/targeted-exome and/or whole-transcriptome sequencing.

  Dataset EGAD00001003441